The HATS study, conducted by Brown and colleagues, showed that simvastatin–niacin combination therapy provided a large reduction in cardiovascular risk compared with placebo. [4] The small population ...

After the failure of Pfizer's good cholesterol-boosting drug, torcetrapib, some Wall Street analysts believe the most promising new treatment option could be a group of niacin-based medicines. Federal ...

April 19, 2012 (Baltimore, Maryland) — When the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) study was ...

Cholesterol is an essential ingredient for human life, a building block for cells that’s used to create hormones, bile, and other vital substances. But too much cholesterol in your blood greatly ...